Cytokinetics Inc reports results for the quarter ended March 31 - Earnings Summary

• Cytokinetics Inc CYTK.OQ reported a quarterly adjusted loss of $1.39​​ per share for the quarter ended March 31, lower than the same quarter last year, when the company reported EPS of $-1.33. The mean expectation of twenty one analysts for the quarter was for a loss of $1.38 per share. Wall Street expected results to range from $-1.59 to $-1.09 per share.

• Revenue rose 89.1% to $1.58 million from a year ago; analysts expected $1.20 million.

• Cytokinetics Inc's reported EPS for the quarter was a loss of $1.36​.

• The company reported a quarterly loss of $161.38 million.

• Cytokinetics Inc shares had fallen by 8.8% this quarter and lost 22.0% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 1.1% in the last three months.​

• In the last 30 days, there have been no negative revisions of earnings estimates

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 19 "strong buy" or "buy," 3 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

• Wall Street's median 12-month price target for Cytokinetics Inc is $75.00

This summary was machine generated from LSEG data May 6 at 09:01 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)